膀胱癌 (Freedman et al.)，為一種從尿路上皮 (Pich et al.) 衍生而來的癌症。為國民十大癌症之一，並具有高死亡率與高醫療成本。在過去研究的資料中發現當交集BCL6高度表現時，會促進膀胱癌細胞週期分布與增生，為一著名之致癌基因。在本篇研究將探討BCL6透過何種路徑影響細胞週期分布與增生，本實驗室過去利用全基因表現矩陣分析 (HumanHT-12v4 Expression BeadChip)中分析，當BCL6上升與靜默有顯著上升下降的前2900個基因並進一步交集得到1310個基因，利用KEGG mapper分析，發現細胞週期路徑與Forkhead box protein O (FOXO)路徑。BCL6透過FOXO pathway，進而影響FOXO3 (Forkhead box O3)之表現。為了證明BCL6透過何種路徑影響FOXO3之表現量與其核質分布，進而影響細胞週期與增生。FOXO3透過其磷酸化位點來調節其功能與表現量，因此利用上調BCL6基因，並且添加LY294002 (PI3K inhibitor)、AZD6244 (MEK/ERK inhibitor)與Gefitinib (EGFR inhinitor)觀察FOXO3磷酸化位點變化、核質分布與細胞週期，發現T24與BFTC905膀胱癌細胞之BCL6透過MEK/ERK，影響下游基因與細胞功能之表現。因此得出結論調節BCL6之活性是一種具有潛在性之治療方式。

Bladder cancer is derived from urothelial, called urothelial carcinoma. It’s the most top ten cancer in Taiwan. In addition, the cancer with high mortality rate and cost of treatment. In past report, the BCL6 induced cell cycle progression and cell proliferation when the BCL6 highly expression in bladder cancer. According to the analysis of whole gene array (HumanHT-12v4 Expression BeadChip) find that 2900 genes regulated by the BCL6. Further analysis of intersection gets 1310 genes. Using the KEGG mapper analysis finds that cell cycle pathway and the FOXO pathway regulated by the BCL6. The BCL6 through the FOXO pathway effects the FOXO3 (Forkhead box O3) expression. To prove the BCL6 how to effect the FOXO3 expression level and nuclear/cytosol distribution, and then affect the cell cycle progression and cell proliferation. The FOXO3 regulates cell function and expression level through the phosphorylation site. For the reason that, to up regulates the BCL6 and add to LY294002 (PI3K inhibitor), AZD6244 (MEK inhibitor), Gefitinib (EGFR inhibitor) to observed the change of phosphorylation site and nuclear/cytosol distribution and cell cycle progression of the FOXO3. Understanding BCL6 effects the downstream genes and cell function through the MEK/ERK in T24 and BFTC905 bladder cancer cell lines. Therefore, to control the activity of BCL6 is a potential therapy.

論文審定書 i
致謝 ii
摘要 iii
Abstract iv
目錄 v
圖次 vii
表次 viii
1、 緒論 1
1.1、簡介膀胱癌 1
1.2、簡介BCL6 2
1.3、簡介FOXO 3
1.4、簡介PI3K pathway 4
1.5、簡介MAPK pathway 4
2、實驗材料與方法 5
2.1、 細胞 5
2.1.1、細胞培養 5
2.1.2、 細胞解凍 5
2.1.3、 繼代培養 6
2.1.4、 細胞冷凍保存 6
2.2、質體製備 7
2.2.1、 質體 7
2.2.2、 質體轉型 7
2.2.3、 質體純化 7
2.2、 基因轉染(transfection) 8
2.3.1、Transient transfection 8
2.3.2、慢病毒感染 (Lentiviral infection) 9
2.4、 cDNA製備與Quantitative real-time PCR (QPCR) 9
2.4.1、 Total RNA萃取 9
2.4.2、 反轉錄聚合酶連鎖反應 (Reverse transcription) 10
2.4.3、 Quantitative real-time (qPCR) 10
2.4.4、 瓊脂膠體電泳 (Agarose gel electrophoresis) 10
2.5、 蛋白質分析 11
2.5.1、蛋白質純化 11
2.5.2、 蛋白質定量 11
2.5.3、 Acrylamide gel 製作 11
2.5.4、 西方點墨法 (western blotting) 12
2.6、核質分離 13
2.7、細胞免疫化學染色 (Immunocytochemistry) 13
3、 結果 21
3.1、BCL6過度表現，影響下游mRNA與蛋白質之表現量 21
3.2、 BCL6基因靜默，影響下游mRNA與蛋白質之表現量 21
3.3、 BCL6 透過MAPK路徑影響細胞週期分布與CDKN1A、CDKN1B之蛋白質表現量 24
3.4、 BCL6透過PI3K路徑影響細胞週期分布與CKKN1A、CKKN1B蛋白質表現量 25
3.5、 BCL6透過EGFR影響細胞週期分布與CDKN1A、CDKN1B之表現量 25
3.6、 在膀胱癌細胞株T24、BFTC905，分別轉染BCL6質體，與基因靜默BCL6觀察FOXO3在細胞核與細胞質之分布。 30
4、討論 33
5、參考文獻 34

Alessi, D. R., M. Deak, A. Casamayor, F. B. Caudwell, N. Morrice, D. G. Norman, P. Gaffney, C. B. Reese, C. N. MacDougall, D. Harbison, A. Ashworth, and M. Bownes. 1997. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Current biology : CB 7(10):776-789.
Alessi, D. R. A., M. Caudwell, B. Cron, P. Morrice, N. Cohen, P. Hemmings, B. A. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. The EMBO Journal 15(23):6541-6551.
Alfred Witjes, J., T. Lebret, E. M. Compérat, N. C. Cowan, M. De Santis, H. M. Bruins, V. Hernández, E. L. Espinós, J. Dunn, M. Rouanne, Y. Neuzillet, E. Veskimäe, A. G. van der Heijden, G. Gakis, and M. J. Ribal. 2017. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Urology 71(3):462-475. doi: 10.1016/j.eururo.2016.06.020
Antoni, S., J. Ferlay, I. Soerjomataram, A. Znaor, A. Jemal, and F. Bray. 2017. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol 71(1):96-108. doi: 10.1016/j.eururo.2016.06.010
Babjuk, M., A. Böhle, M. Burger, O. Capoun, D. Cohen, E. M. Compérat, V. Hernández, E. Kaasinen, J. Palou, M. Rouprêt, B. W. G. van Rhijn, S. F. Shariat, V. Soukup, R. J. Sylvester, and R. Zigeuner. 2016. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology 71(3):447-461. doi: 10.1016/j.eururo.2016.05.041
Baron, B. W., G. Nucifora, N. McCabe, R. Espinosa, 3rd, M. M. Le Beau, and T. W. McKeithan. 1993. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America 90(11):5262-5266.
Bastard, C. 1994. LA23 Rearrangements in Non-Hodgkin''s Lymphoma: Correlation With Histology, Immunophenotype, Karyotype, and Clinical Outcome in 217 Patients blood
Bernardin, F. 1996. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin''s lymphoma without 3q27 translocation.
Bluher, M., B. B. Kahn, and C. R. Kahn. 2003. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science (New York, N.Y.) 299(5606):572-574. doi: 10.1126/science.1078223
Bohle, A., D. Jocham, and P. R. Bock. 2003. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. The Journal of urology 169(1):90-95. doi: 10.1097/01.ju.0000039680.90768.b3
Brunet, A., J. Park, H. Tran, L. S. Hu, B. A. Hemmings, and M. E. Greenberg. 2001. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21(3):952-965. doi: 10.1128/MCB.21.3.952-965.2001
Bubenik, J., M. Baresova, V. Viklicky, J. Jakoubkova, H. Sainerova, and J. Donner. 1973. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. International journal of cancer 11(3):765-773.
Burger, M., J. W. Catto, G. Dalbagni, H. B. Grossman, H. Herr, P. Karakiewicz, W. Kassouf, L. A. Kiemeney, C. La Vecchia, S. Shariat, and Y. Lotan. 2013. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234-241. doi: 10.1016/j.eururo.2012.07.033
Calnan, D. R., and A. Brunet. 2008. The FoxO code. Oncogene 27(16):2276-2288. doi: 10.1038/onc.2008.21
Chang, S. S., S. A. Boorjian, R. Chou, P. E. Clark, S. Daneshmand, B. R. Konety, R. Pruthi, D. Z. Quale, C. R. Ritch, J. D. Seigne, E. C. Skinner, N. D. Smith, and J. M. McKiernan. 2016. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. The Journal of urology 196(4):1021-1029. doi: 10.1016/j.juro.2016.06.049
Cheng, Y. T., Y. L. Li, J. D. Wu, S. B. Long, T. S. Tzai, C. C. Tzeng, and M. D. Lai. 1995. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines. Molecular carcinogenesis 13(3):173-181.
Cooper, M. J., J. J. Haluschak, D. Johnson, S. Schwartz, L. J. Morrison, M. Lippa, G. Hatzivassiliou, and J. Tan. 1994. p53 mutations in bladder carcinoma cell lines. Oncology research 6(12):569-579.
Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231-241.
Daud, A., and B. C. Bastian. 2012. Beyond BRAF in melanoma. Current topics in microbiology and immunology 355:99-117. doi: 10.1007/82_2011_163
del Peso, L., M. Gonzalez-Garcia, C. Page, R. Herrera, and G. Nunez. 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (New York, N.Y.) 278(5338):687-689.
Fernández de Mattos, S., A. Essafi, I. Soeiro, A. M. Pietersen, K. U. Birkenkamp, C. S. Edwards, A. Martino, B. H. Nelson, J. M. Francis, M. C. Jones, J. J. Brosens, P. J. Coffer, and E. W. F. Lam. 2004. FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism. Mol Cell Biol 24(22):10058-10071. doi: 10.1128/mcb.24.22.10058-10071.2004
Freedman, N. D., D. T. Silverman, A. R. Hollenbeck, A. Schatzkin, and C. C. Abnet. 2011. Association between smoking and risk of bladder cancer among men and women. Jama 306(7):737-745. doi: 10.1001/jama.2011.1142
Gupta. 2009. Deregulation of FOXO3A during prostate cancer progression. International Journal of Oncology 34(6)doi: 10.3892/ijo_00000291
Holzenberger, M., J. Dupont, B. Ducos, P. Leneuve, A. Geloen, P. C. Even, P. Cervera, and Y. Le Bouc. 2003. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421(6919):182-187. doi: 10.1038/nature01298
Hsieh, J. L., C. L. Wu, C. H. Lee, and A. L. Shiau. 2003. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clinical cancer research : an official journal of the American Association for Cancer Research 9(1):338-345.
Jardin, F., P. Gaulard, G. Buchonnet, N. Contentin, S. Lepretre, P. Lenain, A. Stamatoullas, J. M. Picquenot, C. Duval, F. Parmentier, H. Tilly, and C. Bastard. 2002. Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia 16(11):2309-2317. doi: 10.1038/sj.leu.2402707
Knowles, M. A., and C. D. Hurst. 2015. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature reviews. Cancer 15(1):25-41. doi: 10.1038/nrc3817
Kodaki, T., R. Woscholski, B. Hallberg, P. Rodriguez-Viciana, J. Downward, and P. J. Parker. 1994. The activation of phosphatidylinositol 3-kinase by Ras. Current biology : CB 4(9):798-806.
Lerner, S. P. 2016. Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines. Nature reviews. Urology 13(8):440-441. doi: 10.1038/nrurol.2016.114
Mackay, J. E., M. 2002. The Tobacco Atlas.
Margalit, O., H. Amram, N. Amariglio, A. J. Simon, S. Shaklai, G. Granot, N. Minsky, A. Shimoni, A. Harmelin, D. Givol, M. Shohat, M. Oren, and G. Rechavi. 2006. BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. Blood 107(4):1599-1607. doi: 10.1182/blood-2005-04-1629
Markl, I. D., and P. A. Jones. 1998. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer research 58(23):5348-5353.
McCain, J. 2012. The MAPK (ERK) Pathway Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P&T®
Mendoza, M. C., E. E. Er, and J. Blenis. 2011. The Ras-ERK and PI3K-mTOR Pathways: Cross-talk and Compensation. Trends in biochemical sciences 36(6):320-328. doi: 10.1016/j.tibs.2011.03.006
Moolgavkar, S. H., and R. G. Stevens. 1981. Smoking and cancers of bladder and pancreas: risks and temporal trends. Journal of the National Cancer Institute 67(1):15-23.
Nakae, J., W. H. Biggs, 3rd, T. Kitamura, W. K. Cavenee, C. V. Wright, K. C. Arden, and D. Accili. 2002. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nature genetics 32(2):245-253. doi: 10.1038/ng890
Nakamura, Y., T. Miki, I. Miura, K. Hashimoto, A. Miura, K. Akimoto, S. Hirosawa, K. Saito, H. Enokihara, S. Furusawa, and H. Shishido. 1996. Internal DNA deletion within the BCL-6 gene on untranslocated chromosome in non-Hodgkin''s lymphoma with 3q27 abnormality. Leukemia 10(4):658-661.
Oestreich, K. J., S. E. Mohn, and A. S. Weinmann. 2012. Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. Nature immunology 13(4):405-411. doi: 10.1038/ni.2242
Offit , K., F. L. Coco , D. C. Louie , N. Z. Parsa , D. Leung , C. Portlock , B. H. Ye , F. Lista , D. A. Filippa , A. Rosenbaum , M. Ladanyi , S. Jhanwar , R. Dalla-Favera , and R. S. K. Chaganti 1994. Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma. New England Journal of Medicine 331(2):74-80. doi: 10.1056/nejm199407143310202
Phan, R. T., M. Saito, K. Basso, H. Niu, and R. Dalla-Favera. 2005. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nature immunology 6(10):1054-1060. doi: 10.1038/ni1245
Pich, A., L. Chiusa, A. Formiconi, D. Galliano, P. Bortolin, and R. Navone. 2001. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. The American journal of surgical pathology 25(12):1528-1533.
Power, N. E., and J. Izawa. 2016. Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer 2(1):27-36. doi: 10.3233/blc-150034
Qi, W., C. R. Weber, K. Wasland, H. Roy, R. Wali, S. Joshi, and S. D. Savkovic. 2011. Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. Am J Physiol Gastrointest Liver Physiol 300(2):G264-272. doi: 10.1152/ajpgi.00416.2010
Rodriguez-Viciana, P., P. H. Warne, R. Dhand, B. Vanhaesebroeck, I. Gout, M. J. Fry, M. D. Waterfield, and J. Downward. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370(6490):527-532. doi: 10.1038/370527a0
Sadeghi, S., and J. A. Garcia. 2012. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Semin Oncol 39(5):608-614. doi: 10.1053/j.seminoncol.2012.08.004
Sanli, O., J. Dobruch, M. A. Knowles, M. Burger, M. Alemozaffar, M. E. Nielsen, and Y. Lotan. 2017. Bladder cancer. Nat Rev Dis Primers 3:17022. doi: 10.1038/nrdp.2017.22
Sjolander, A., K. Yamamoto, B. E. Huber, and E. G. Lapetina. 1991. Association of p21ras with phosphatidylinositol 3-kinase. Proceedings of the National Academy of Sciences of the United States of America 88(18):7908-7912.
Sylvester, R. J., M. A. Brausi, W. J. Kirkels, W. Hoeltl, F. Calais Da Silva, P. H. Powell, S. Prescott, Z. Kirkali, C. van de Beek, T. Gorlia, and T. M. de Reijke. 2010. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766-773. doi: 10.1016/j.eururo.2009.12.024
Tang, Y., A. R. Simoneau, J. Xie, B. Shahandeh, and X. Zi. 2008. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev Res (Phila) 1(6):439-451. doi: 10.1158/1940-6207.CAPR-08-0165
Tzeng, C. C., H. S. Liu, C. Li, Y. T. Jin, R. M. Chen, W. H. Yang, and J. S. Lin. 1996. Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer research 16(4a):1797-1804.
Tzivion, G., M. Dobson, and G. Ramakrishnan. 2011. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813(11):1938-1945. doi: 10.1016/j.bbamcr.2011.06.002
Viglietto, G., M. L. Motti, P. Bruni, R. M. Melillo, A. D''Alessio, D. Califano, F. Vinci, G. Chiappetta, P. Tsichlis, A. Bellacosa, A. Fusco, and M. Santoro. 2002. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nature medicine 8(10):1136-1144. doi: 10.1038/nm762
Wang, Y., X.-L. Kang, F.-C. Zeng, C.-J. Xu, J.-Q. Zhou, and D.-N. Luo. 2017. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer. Pathology - Research and Practice 213(7):766-772. doi: http://dx.doi.org/10.1016/j.prp.2017.04.004
Wu, X. R. 2005. Urothelial tumorigenesis: a tale of divergent pathways. Nature reviews. Cancer 5(9):713-725. doi: 10.1038/nrc1697
Yang, J. Y., C. S. Zong, W. Xia, H. Yamaguchi, Q. Ding, X. Xie, J. Y. Lang, C. C. Lai, C. J. Chang, W. C. Huang, H. Huang, H. P. Kuo, D. F. Lee, L. Y. Li, H. C. Lien, X. Cheng, K. J. Chang, C. D. Hsiao, F. J. Tsai, C. H. Tsai, A. A. Sahin, W. J. Muller, G. B. Mills, D. Yu, G. N. Hortobagyi, and M. C. Hung. 2008. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138-148. doi: 10.1038/ncb1676
Ye, B. H., S. Chaganti, C. C. Chang, H. Niu, P. Corradini, R. S. Chaganti, and R. Dalla-Favera. 1995. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. The EMBO Journal 14(24):6209-6217.
Yee, D. S., N. M. Ishill, W. T. Lowrance, H. W. Herr, and E. B. Elkin. 2011. Ethnic differences in bladder cancer survival. Urology 78(3):544-549. doi: 10.1016/j.urology.2011.02.042
Zhou, B. P., Y. Liao, W. Xia, B. Spohn, M. H. Lee, and M. C. Hung. 2001. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3(3):245-252. doi: 10.1038/35060032